Michael Fauscette’s Post

𝗥𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘇𝗲 𝗚��𝗖𝗥 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝘄𝗶𝘁𝗵 𝗿𝗲𝗮𝗹-𝘁𝗶𝗺𝗲, 𝗹𝗮𝗯𝗲𝗹-𝗳𝗿𝗲𝗲 𝗶𝗺𝗽𝗲𝗱𝗮𝗻𝗰𝗲 𝗺𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴! 🔬 Are you ready to elevate your understanding of G-protein coupled receptors (GPCRs)? Join us for an engaging webinar where we delve into the innovative method of profiling GPCRs using non-invasive, real-time impedance monitoring. 𝗪𝗵𝘆 𝗚𝗣𝗖𝗥𝘀 𝗺𝗮𝘁𝘁𝗲𝗿? GPCRs are among the most targeted receptors in drug development, constituting about 40% of all prescription drugs. Traditional screening methods are often invasive and limited to endpoint assays, which don’t capture the full dynamics of cellular responses. 𝗪𝗲𝗯𝗶𝗻𝗮𝗿 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: 🌟 Explore label-free impedance analysis: Learn how this technology allows continuous, real-time monitoring of cellular responses without the need for invasive procedures. 🌟 Understand the technology: Understand the physical principles that make impedance monitoring a powerful tool in pharmacology. 🌟 Applications in GPCR Pharmacology such as conducting agonist and antagonist assays, analyzing dose-response relationships, studying receptor desensitization, profiling signal transduction pathways. 📅 Date and Time: July 3rd, 2024; 4:00 PM - 5:00 PM CEST 🎤 Speaker: Prof. Joachim Wegener, Universität Regensburg & Fraunhofer EMFT Don't miss this opportunity to learn about cutting-edge techniques that can significantly enhance your GPCR research. 👉 Secure your spot now! Register here: https://ow.ly/LZL650S1UoW #GPCR #Webinar #DrugDiscovery #Pharmacology #ImpedanceMonitoring #RealTimeData #NonInvasiveResearch #InnovativeTechniques

𝗝𝗼𝗶𝗻 𝘂𝘀 𝗮𝘁 𝘁𝗵𝗲 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝘁𝗼 𝘂𝗻𝗹𝗼𝗰𝗸 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗚𝗣𝗖𝗥 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝘄𝗶𝘁𝗵 𝗻𝗼𝗻-𝗶𝗻𝘃𝗮𝘀𝗶𝘃𝗲, 𝗿𝗲𝗮𝗹-𝘁𝗶𝗺𝗲 𝗶𝗺𝗽𝗲𝗱𝗮𝗻𝗰𝗲 𝗺𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴! 🌟 G-protein coupled receptors (GPCRs) are pivotal in drug discovery, with around 40% of all prescription drugs targeting these critical receptors. Traditional screening methods often require invasive procedures and fail to capture the dynamic nature of cellular responses. Join us for an insightful webinar to explore a game-changing approach: profiling GPCRs using non-invasive, real-time impedance monitoring. 📅 Date and Time: July 3rd, 2024; 4:00 PM - 5:00 PM CEST 🎤 Speaker: Prof. Joachim Wegener, Universität Regensburg & Fraunhofer EMFT 𝗪𝗲𝗯𝗶𝗻𝗮𝗿 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: ▪️ Discover how label-free impedance measurements revolutionize GPCR pharmacology ▪️ Dive into the technology and physical principles behind impedance analysis ▪️ Learn about applications in: ▪️ Agonist and antagonist assays ▪️ Dose-response relationships ▪️ Receptor desensitization ▪️ Signal transduction profiling Say goodbye to invasive methods and endpoint assays. Embrace real-time, label-free monitoring to enhance your research precision and efficacy. 👉 Register now to secure your spot and transform your GPCR research! Register here: https://ow.ly/EmU250S1SCw #GPCR #AtlaZ #DrugDiscovery #Webinar #Pharmacology #ResearchInnovation #RealTimeMonitoring #ImpedanceAnalysis #LabelFree #CellAnalytics

The therapeutic impact of monoclonal antibodies (mAbs) is evident in the thriving market, the global antibody market grew from $188.18 billion in 2022 to $209.98 billion in 2023. And it is expected to reach $330.35 billion by 2027. The pharmaceutical industry has responded with an increased focus on mAbs in the pipeline, leading to innovative approaches for refining the antibody development process. This surge underscores the industry's acknowledgment of mAbs as crucial therapeutic agents, necessitating continuous efforts to optimize and advance the antibody pipeline. Simultaneously, Artificial Intelligence (AI) and deep learning, having made significant progress, now play a pivotal role in the intricate tasks of designing and optimizing antibodies. ⁠BoltPro employs deep learning algorithms to create novel antibodies, focusing on achieving optimal binding and developability characteristics. Try Boltpro beta now: https://lnkd.in/gtUMnRad #Boltzmann #deeplearning #BoltPro #ai #ml #proteinengineering #antibodies #antibodydiscovery #antibodytherapeutics #drugdiscovery #aidrugdiscovery #computationalbiology #bioinformatics #pharma #biotech Image Credits: https://lnkd.in/gR8fYC9b

The global monoclonal antibodies (mAbs) market has experienced significant growth, with the market value surging from $188.18 billion in 2022 to $209.98 billion in 2023. Projections indicate that it is on track to reach an impressive $330.35 billion by 2027. This remarkable expansion underscores the pharmaceutical industry's heightened focus on mAbs, prompting the development of innovative approaches to refine the antibody development process. Recognizing mAbs as pivotal therapeutic agents, the industry is committed to ongoing efforts aimed at optimizing and advancing the antibody pipeline. Notably, the integration of Artificial Intelligence (AI) and deep learning has played a transformative role in designing and optimizing antibodies, marking a significant milestone in antibody development. In this dynamic landscape, the utilization of AI in drug discovery processes is paramount. Medvolt, at the forefront of AI-based drug discovery, offers a groundbreaking approach to expedite the drug discovery journey. Leveraging the power of AI, Medvolt streamlines and enhances the identification and development of novel drugs. We invite you to experience firsthand the revolutionary impact of Medvolt's cutting-edge technology through our demo sessions, showcasing how AI can reshape and accelerate your drug discovery initiatives. 𝐅𝐞𝐞𝐥 𝐟𝐫𝐞𝐞 𝐭𝐨 𝐜𝐨𝐧𝐭𝐚𝐜𝐭 𝐮𝐬 𝐢𝐟 𝐲𝐨𝐮 𝐡𝐚𝐯𝐞 𝐚𝐧𝐲 𝐢𝐧𝐪𝐮𝐢𝐫𝐢𝐞𝐬 𝐨𝐫 𝐫𝐞𝐪𝐮𝐢𝐫𝐞 𝐚 𝐝𝐞𝐦𝐨𝐧𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧. 𝐖𝐞'𝐫𝐞 𝐡𝐞𝐫𝐞 𝐭𝐨 𝐚𝐬𝐬𝐢𝐬𝐭 𝐲𝐨𝐮 𝐚𝐧𝐝 𝐩𝐫𝐨𝐯𝐢𝐝𝐞 𝐜𝐥𝐚𝐫𝐢𝐭𝐲. Email: contact@medvolt.ai Website: https://www.medvolt.ai #drugdiscovery #python #deeplearning #linux #pipeline #genomics #moleculardocking #virtualscreening #therapeutics #drug #cancertreatment #health #cancertherapeutics #cancertherapy #generativeai #medvolt

What’s holding back progress in developing drugs targeted at RNA and protein-protein interactions? Poor quality analytical data. Here’s why. In this article for pharmaphorum our CEO Gordon Hamilton discusses the opportunities and challenges in expanding the drug target universe to include so-called ‘undruggable’ targets like RNA and protein-protein interactions. https://lnkd.in/e-CuWNx5 The big issue is a lack of detailed information about mechanism of action, off-target effects, and binding kinetics, particularly at the hit-to-lead and lead optimisation stage. This results in the selection and progression of sub-optimal lead compounds through the drug development pipeline. Unfortunately, current analytical techniques for studying molecular interactions between RNA, proteins and small molecules are inherently limited, due to being indirect, static, unrepresentative or unsuitable for use at scale. Our MAGNA™ technology is a unique, scalable platform for probing molecular interactions with a wide range of applications across the drug discovery pipeline. Based on magnetic force spectroscopy, MAGNA delivers direct, real-time measurement of dynamic interactions across thousands of individual molecules. We’re currently seeking partnerships with pioneering biopharma companies interested in exploring exciting novel targets in the RNA and protein-protein interaction space to accelerate next-generation therapeutics to the clinic. Check out our website and get in touch to find out more: https://depixus.com/ #DrugDiscovery #biotherapeutics #SmallMolecules #RNATherapeutics

Google DeepMind and its spinoff drug discovery firm Isomorphic Labs rolled out a new version of AlphaFold. This AI model can predict the structure and interactions of all life's molecules, including proteins and DNA. Further, the firm is also collaborating with pharmaceutical companies to apply it to real-world drug design challenges with a goal to develop new "life-changing" treatments for patients. #AI #Google #AIinHealthcare #Medical #DeepMind

New platform solves key problems in targeted drug delivery - Phys.org >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #competitivemarketing #biotech #healthcare

What do you think is the most innovative approach to pharmaceutical care? ✏️ Certainly, here are a few more innovative approaches to pharmaceutical care: - Microbiome-based Therapies: Exploring the role of the gut microbiome in drug metabolism and developing therapies that consider this factor. - Gene Editing and CRISPR: Advancements in gene editing techniques for potential treatment of genetic diseases. - Real-World Evidence (RWE): Utilizing data from real-world patient experiences to inform drug development and decision-making. - Drug-Device Combinations: Developing drugs that work in tandem with specialized delivery devices, improving treatment effectiveness. - Biosimilars and Biobetters: Creating biologic drugs that mimic or improve upon existing biologics, potentially lowering costs. - Natural Products and Traditional Medicine: Investigating traditional remedies and natural products for novel pharmaceutical applications. - 3D Drug Screening: Using 3D cell cultures and organoids for more accurate drug testing and toxicity assessment. - Virtual Clinical Trials: Conducting clinical trials using digital platforms and remote monitoring, increasing efficiency and patient participation. - AI Chatbots and Virtual Assistants: Using AI-powered chatbots to provide medication information, reminders, and support to patients. These approaches collectively represent a diverse range of innovations in the field of pharmaceutical care.

Somehow we are already approaching the mid way point of 2024! Pharmaceutical Drug Development has made some interesting strides during the last six months. Exciting Breakthroughs in Drug Development in 2024 Alzheimer’s Disease Treatment Eli Lilly is set to debut a new treatment for Alzheimer’s disease that targets amyloid, the protein that builds up in the brains of patients. In studies submitted to the U.S. Food and Drug Administration (FDA), people receiving the drug experienced 35% slower cognitive decline and 40% less decline in their ability to perform daily activities. This efficacy is slightly higher than existing medications for the neurodegenerative disease. The FDA is expected to make a decision about the drug in early 2024. Innovative Blood-Disorder Treatments After approving the first CRISPR treatment, Casgevy, for sickle cell anemia, the FDA is reviewing the same therapy for another genetic blood disorder called beta thalassemia. This one-time treatment allows people to make more healthy blood cells, reducing the number of painful episodes. The FDA is also considering other gene-based treatments that don’t use CRISPR but rely on more traditional virus-based methods. One such treatment is for hemophilia B, which has shown to lower the risk of annual bleeding by 71% in studies. Novel Schizophrenia Drug Later in the year, the FDA will review a new drug treatment for schizophrenia — the first for the psychiatric condition in decades. Karuna Therapeutics has improved upon existing antipsychotics by targeting a different brain chemical than existing medications. In a study, the drug helped to reduce the extremes of symptoms that are typical of the condition. The Ascension of AI in R&D The field of AI has seen significant breakthroughs in chemistry and drug discovery. Generative AI is impacting drug discovery, machine learning is being used more in environmental research, and large language models like ChatGPT are being tested in healthcare applications and clinical settings. Many scientists are keeping an eye on AlphaFold, DeepMind’s protein structure prediction software that revolutionized how proteins are understood. These breakthroughs represent just a fraction of the exciting developments in drug discovery and development in 2024. As we continue to push the boundaries of science and technology, we can look forward to even more innovative treatments that have the potential to improve and save lives. #Biotech #BioPharma #Drugdevelopment

A Complete Guide to 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 - [PDF Guide] ➡ 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲: https://lnkd.in/d4ZD_3mm Biologics are pharmaceutical products that are manufactured using biological processes rather than chemical synthesis. They are typically derived from living organisms such as humans, animals, microorganisms, or plants. Biologics include a wide range of products such as vaccines, blood components, gene therapies, tissues, and recombinant therapeutic proteins. These drugs have revolutionized the treatment of various diseases, including cancer, autoimmune disorders, and genetic conditions. One key characteristic of biologics is their complexity. Unlike small molecule drugs, which have well-defined structures, biologics are often large, complex molecules with intricate structures. This complexity can pose challenges in terms of manufacturing, quality control, and characterization. Biologics are typically produced using biotechnology techniques such as recombinant DNA technology, cell culture, and protein purification. Because of their complexity and the processes involved in their manufacture, biologics are subject to strict regulatory oversight to ensure their safety, efficacy, and quality. These drugs have significantly impacted the field of medicine, offering new treatment options for patients with serious and often life-threatening conditions. However, they can also be expensive to develop and produce, which can limit access for some patients. Nonetheless, ongoing research and advancements in biotechnology continue to drive innovation in the field of biologics, offering hope for improved treatments and cures for a wide range of diseases.